Related papers: HIBMatch: Hypergraph Information Bottleneck for Se…
Alzheimer's disease (AD) progression follows a complex continuum from normal cognition (NC) through mild cognitive impairment (MCI) to dementia, yet most deep learning approaches oversimplify this into discrete classification tasks. This…
The rapid global aging trend has led to an increase in dementia cases, including Alzheimer's disease, underscoring the urgent need for early and accurate diagnostic methods. Traditional diagnostic techniques, such as cognitive tests,…
Accurate diagnosis of Alzheimer's disease (AD) requires effectively integrating multimodal data and clinical expertise. However, existing methods often struggle to fully utilize multimodal information and lack structured mechanisms to…
Alzheimer's disease is a neurogenerative disease that alters memories, cognitive functions leading to death. Early diagnosis of the disease, by detection of the preliminary stage, called Mild Cognitive Impairment (MCI), remains a…
Unveiling pathological brain changes associated with Alzheimer's disease (AD) is a challenging task especially that people do not show symptoms of dementia until it is late. Over the past years, neuroimaging techniques paved the way for…
The current clinical diagnosis framework of Alzheimer's disease (AD) involves multiple modalities acquired from multiple diagnosis stages, each with distinct usage and cost. Previous AD diagnosis research has predominantly focused on how to…
Alzheimer's disease (AD) is a degenerative brain disease impairing a person's ability to perform day to day activities. The clinical manifestations of Alzheimer's disease are characterized by heterogeneity in age, disease span, progression…
FDG-PET reveals altered brain metabolism in individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD). Some biomarkers derived from FDG-PET by computer-aided-diagnosis (CAD) technologies have been proved that they can…
Brain transcriptomics provides insights into the molecular mechanisms by which the brain coordinates its functions and processes. However, existing multimodal methods for predicting Alzheimer's disease (AD) primarily rely on imaging and…
The path signature is a means of feature generation that can encode nonlinear interactions in the data as well as the usual linear features. It can distinguish the ordering of time-sequenced changes: for example whether or not the…
Alzheimer's disease, a neurodegenerative disorder, is associated with neural, genetic, and proteomic factors while affecting multiple cognitive and behavioral faculties. Traditional AD prediction largely focuses on univariate disease…
Pretrained Multimodal Large Language Models (MLLMs) are increasingly used in sensitive domains such as medical AI, where privacy regulations like HIPAA and GDPR require specific removal of individuals' or institutions' data. This motivates…
Alzheimer's disease (AD) is an irreversible neurode generative disease of the brain.The disease may causes memory loss, difficulty communicating and disorientation. For the diagnosis of Alzheimer's disease, a series of scales are often…
Magnetic Resonance Imaging (MRI) plays a pivotal role in the early diagnosis and monitoring of Alzheimer's disease (AD). However, the subtle structural variations in brain MRI scans often pose challenges for conventional deep learning…
Mild cognitive impairment (MCI) is the prodromal stage of Alzheimer's disease (AD) and thus enrolling MCI subjects to undergo clinical trials is worthwhile. However, MCI groups usually show significant diversity and heterogeneity in the…
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders worldwide. As it progresses, it leads to the deterioration of cognitive functions. Since AD is irreversible, early diagnosis is crucial for managing its…
The early detection of Alzheimer's Disease is imperative to ensure early treatment and improve patient outcomes. There has consequently been extenstive research into detecting AD and its intermediate phase, mild cognitive impairment (MCI).…
We propose a disease classification model, called the QC-SPHARM, for the early detection of the Alzheimer's Disease (AD). The proposed QC-SPHARM can distinguish between normal control (NC) subjects and AD patients, as well as between…
Reliable Alzheimer's disease (AD) diagnosis increasingly relies on multimodal assessments combining structural Magnetic Resonance Imaging (MRI) and Electronic Health Records (EHR). However, deploying these models is bottlenecked by modality…
This study is based on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset and aims to explore early detection and disease progression in Alzheimer's disease (AD). We employ innovative data preprocessing strategies, including the…